| Representation of minorities and women in oncology clinical trials: review of the past 14 years N Duma, J Vera Aguilera, J Paludo, CL Haddox, M Gonzalez Velez, ... Journal of oncology practice 14 (1), e1-e10, 2018 | 323 | 2018 |
| Sex differences in tolerability to anti‐programmed cell death protein 1 therapy in patients with metastatic melanoma and non‐small cell lung cancer: are we all equal? N Duma, A Abdel‐Ghani, S Yadav, KP Hoversten, CT Reed, AN Sitek, ... The oncologist 24 (11), e1148-e1155, 2019 | 98 | 2019 |
| Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study JJ Castillo, G Itchaki, J Paludo, M Varettoni, C Buske, TA Eyre, JC Chavez, ... Blood, The Journal of the American Society of Hematology 133 (4), 299-305, 2019 | 88 | 2019 |
| Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia J Paludo, JP Abeykoon, A Shreders, SM Ansell, S Kumar, S Ailawadhi, ... Annals of hematology 97, 1417-1425, 2018 | 86 | 2018 |
| MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia JP Abeykoon, J Paludo, RL King, SM Ansell, MA Gertz, BR LaPlant, ... American journal of hematology 93 (2), 187-194, 2018 | 67 | 2018 |
| Ruxolitinib as first‐line treatment in secondary hemophagocytic lymphohistiocytosis: a single patient experience J Slostad, P Hoversten, CL Haddox, K Cisak, J Paludo, A Tefferi American journal of hematology 93 (2), E47-E49, 2018 | 62 | 2018 |
| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma J Paludo, JR Mikhael, BR LaPlant, AE Halvorson, S Kumar, MA Gertz, ... Blood, The Journal of the American Society of Hematology 130 (10), 1198-1204, 2017 | 62 | 2017 |
| Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium Y Wang, P Jain, FL Locke, MJ Maurer, MJ Frank, JL Munoz, S Dahiya, ... Journal of clinical oncology 41 (14), 2594-2606, 2023 | 54 | 2023 |
| Myelomatous Involvement of the Central Nervous System J Paludo, U Painuly, S Kumar, WI Gonsalves, V Rajkumar, F Buadi, ... Clinical Lymphoma Myeloma and Leukemia, 2016 | 52 | 2016 |
| Waldenström macroglobulinemia: What a hematologist needs to know P Kapoor, J Paludo, N Vallumsetla, PR Greipp Blood Reviews 29 (5), 301-319, 2015 | 52 | 2015 |
| Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients JV Aguilera, J Paludo, RR McWilliams, H Zhang, Y Li, AB Kumar, J Failing, ... Melanoma research 30 (4), 364-375, 2020 | 51 | 2020 |
| Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia S Jalali, T Price-Troska, J Paludo, J Villasboas, HJ Kim, ZZ Yang, ... Blood advances 2 (15), 1985-1997, 2018 | 45 | 2018 |
| Characterization of comorbidities limiting the recruitment of patients in early phase clinical trials N Duma, SM Kothadia, TU Azam, S Yadav, J Paludo, J Vera Aguilera, ... The oncologist 24 (1), 96-102, 2019 | 40 | 2019 |
| Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia J Paludo, JP Abeykoon, S Kumar, A Shreders, S Ailawadhi, MA Gertz, ... British journal of haematology 179 (1), 98-105, 2017 | 34 | 2017 |
| Representation of minorities and women in oncology clinical trials: review of the past 14 years. J Oncol Pract. 2018; 14 (1): e1–e10 N Duma, J Vera Aguilera, J Paludo, CL Haddox, M Gonzalez Velez, ... Duma et al. conduct a survey of 1012, 2017 | 33 | 2017 |
| Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? O Saifi, WG Breen, SC Lester, WG Rule, B Stish, A Rosenthal, J Munoz, ... Radiotherapy and Oncology 166, 171-179, 2022 | 32 | 2022 |
| Extraskeletal osteosarcoma: outcomes and the role of chemotherapy J Paludo, K Fritchie, CL Haddox, PS Rose, CAS Arndt, RS Marks, ... American journal of clinical oncology 41 (9), 832-837, 2018 | 31 | 2018 |
| Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma J Cook, KW Peng, TE Witzig, SM Broski, JC Villasboas, J Paludo, ... Blood Advances 6 (11), 3268-3279, 2022 | 30 | 2022 |
| Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant S Sidana, AC Dueck, G Thanarajasingam, JM Griffin, C Thompson, ... Transplantation and cellular therapy 28 (8), 473-482, 2022 | 27 | 2022 |
| Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real world experience from the US Lymphoma CAR T Consortium Y Wang, P Jain, FL Locke, J Munoz, MJ Maurer, A Beitinjaneh, MJ Frank, ... Blood 138, 744, 2021 | 27 | 2021 |
Vincent RajkumarMayo ClinicVerified email at mayo.edu
